Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziftomenib in Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
NCT07007312Phase 3Recruiting
- Sponsor
- Kura Oncology
- Start
- Sep 2025
- Primary completion
- Nov 2031
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of ziftomenib in acute myeloid leukemia (AML), sponsored by Kura Oncology. Started Sep 2025; status: recruiting.
02
Drugs
ziftomenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07007312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007312.